Last reviewed · How we verify
gabapentin + tramadol
gabapentin + tramadol is a Analgesic combination (anticonvulsant + opioid) Small molecule drug developed by Southwest Hospital, China. It is currently FDA-approved for Moderate to severe pain (neuropathic and somatic), Postoperative pain, Chronic pain conditions.
This combination enhances pain relief by increasing neuronal calcium channel inhibition (gabapentin) and inhibiting monoamine reuptake while activating opioid receptors (tramadol).
This combination enhances pain relief by increasing neuronal calcium channel inhibition (gabapentin) and inhibiting monoamine reuptake while activating opioid receptors (tramadol). Used for Moderate to severe pain (neuropathic and somatic), Postoperative pain, Chronic pain conditions.
At a glance
| Generic name | gabapentin + tramadol |
|---|---|
| Sponsor | Southwest Hospital, China |
| Drug class | Analgesic combination (anticonvulsant + opioid) |
| Target | Voltage-gated calcium channels (Cav2.1, Cav2.2); μ-opioid receptor; serotonin and norepinephrine transporters |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Gabapentin reduces neuropathic pain by blocking voltage-gated calcium channels in the central nervous system, decreasing neurotransmitter release. Tramadol is a weak opioid agonist that also inhibits reuptake of serotonin and norepinephrine, providing multimodal analgesia. Together, they target pain through complementary mechanisms—one primarily neuropathic and one opioid-based with monoaminergic activity.
Approved indications
- Moderate to severe pain (neuropathic and somatic)
- Postoperative pain
- Chronic pain conditions
Common side effects
- Dizziness
- Somnolence
- Nausea
- Headache
- Constipation
- Seizures (tramadol-related)
- Serotonin syndrome risk
Key clinical trials
- Effectiveness of AI-Guided Exercise and Pain Neuroscience Education for Fibromyalgia (FIBROIA) (NA)
- Dronabinol On the Pain Experience (PHASE4)
- Treatment Outcomes Under a Standardized Treatment Protocol in Patients Suffered Substance Abuse Related Voiding Dysfunction
- Opioid-Free Orthopaedic Surgery (NA)
- Preemptive Oral Gabapentin and Tramadol on Postoperative Pain After Knee Arthroscopy (NA)
- ACL-R Opioid Sparing Study (PHASE3)
- Effectiveness of Conventional Therapy Plus Pulsed-Radiofrequency for Herniated Nucleus Pulposus (NA)
- Opioid-Free Pain Control Regiment Following Robotic Radical Prostatectomy (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- gabapentin + tramadol CI brief — competitive landscape report
- gabapentin + tramadol updates RSS · CI watch RSS
- Southwest Hospital, China portfolio CI
Frequently asked questions about gabapentin + tramadol
What is gabapentin + tramadol?
How does gabapentin + tramadol work?
What is gabapentin + tramadol used for?
Who makes gabapentin + tramadol?
What drug class is gabapentin + tramadol in?
What development phase is gabapentin + tramadol in?
What are the side effects of gabapentin + tramadol?
What does gabapentin + tramadol target?
Related
- Drug class: All Analgesic combination (anticonvulsant + opioid) drugs
- Target: All drugs targeting Voltage-gated calcium channels (Cav2.1, Cav2.2); μ-opioid receptor; serotonin and norepinephrine transporters
- Manufacturer: Southwest Hospital, China — full pipeline
- Therapeutic area: All drugs in Pain Management
- Indication: Drugs for Moderate to severe pain (neuropathic and somatic)
- Indication: Drugs for Postoperative pain
- Indication: Drugs for Chronic pain conditions
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing